Opinion|Videos|October 14, 2024
Impact of Adjuvant Immunotherapy on First-Line Treatment Decisions for Newly Diagnosed mRCC
Author(s)Rana R. McKay, MD
Panelists discuss how the introduction of adjuvant immunotherapy has influenced their first-line treatment decisions for patients with newly diagnosed metastatic renal cell carcinoma.
Advertisement
Episodes in this series
- Please discuss how the introduction of adjuvant immunotherapy has impacted your first-line treatment decisions for patients with newly diagnosed metastatic renal cell carcinoma?
Advertisement
Related to this article
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
FDA approves belzutifan plus lenvatinib for advanced clear cell RCC after PD-1/PD-L1 therapy, based on PFS and response rate benefit vs cabozantinib.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Rusfertide Redefines the Polycythemia Vera Paradigm
2
FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC
3
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
4
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
5